Edition:
India

People: ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

25.34USD
1:30am IST
Change (% chg)

$0.20 (+0.80%)
Prev Close
$25.14
Open
$24.80
Day's High
$25.39
Day's Low
$24.03
Volume
463,859
Avg. Vol
504,667
52-wk High
$28.67
52-wk Low
$12.80

Soland, Daniel 

Mr. Daniel B. Soland is Independent Director of the Company. Mr. Soland has been Chief Executive Officer of uniQure N.V., a human gene therapy company, since December 2015. Mr. Soland previously served as Senior Vice President and Chief Operating Officer of ViroPharma, Inc. starting in 2008 until it was acquired in 2014, and as Vice President and Chief Commercial Officer of ViroPharma from 2006 to 2008. During his tenure at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States. Mr. Soland served as President, Chiron Vaccines, of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr. Soland worked for GlaxoSmithKline in increasing roles of responsibility from 1993 to 2002, including as Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the board of DBV Technologies SA. The NCG Committee believes that Mr. Soland’s extensive commercial experience brings valuable knowledge and expertise to the Board as the Company transitions to a commercial entity. Mr. Soland holds a B.S. in Pharmacy degree from the University of Iowa.

Basic Compensation

Total Annual Compensation, USD 70,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 505,196
Fiscal Year Total, USD 575,196

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stephen Biggar

352,326

Srdjan Stankovic

7,196,470

Stephen Davis

15,158,100

Elena Ridloff

--

Austin Kim

--

Michael Yang

12,103,900
As Of  31 Dec 2017